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Background: The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal
stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment.
Methods: Nationwide population-based data were retrieved from the Netherlands Cancer Registry.
All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined
as any treatment within the first 6–9months after diagnosis, was studied. Age-standardized incidence
was calculated according to the European standard population. Changes in incidence were evaluated
by calculating the estimated annual percentage change (EAPC). Relative survival was used for survival
calculations with follow-up available to January 2017.
Results: A total of 1749 patients (54⋅0 per cent male and median age 66 years) were diagnosed with a
GIST. The incidence of non-metastatic GIST increased from 3⋅1 per million person-years in 2001 to 7⋅0
per million person-years in 2012; the EAPC was 7⋅1 (95 per cent c.i. 4⋅1 to 10⋅2) per cent (P< 0⋅001).
The incidence of primary metastatic GIST was 1⋅3 per million person-years, in both 2001 and 2012. The
5-year relative survival rate increased from 71⋅0 per cent in 2001–2004 to 81⋅4 per cent in 2009–2012.
Women had a better outcome than men. Overall, patients with primary metastatic GIST had a 5-year
relative survival rate of 48⋅2 (95 per cent c.i. 42⋅0 to 54⋅2) per cent compared with 88⋅8 (86⋅0 to 91⋅4) per
cent in those with non-metastatic GIST.
Conclusion: This population-based nationwide study found an incidence of GIST in the Netherlands
of approximately 8 per million person-years. One in five patients presented with metastatic disease, but
relative survival improved significantly over time for all patients with GIST in the imatinib era.
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Introduction
Gastrointestinal stromal tumours (GISTs) are the most
common mesenchymal neoplasms in the gastrointestinal
(GI) tract, affecting 10–15 people per million per year in
Western countries1–3. The incidence is estimated to be
higher for the Asian population at 16–20 per million per
year4,5, whereas it is estimated to be 6⋅8 per million per
year in the USA6. There are no studies available with data
on global incidence and prevalence.
The identification of GIST originating from the inter-
stitial cells of Cajal and gain-of-functions mutations in KIT
and PDGFRA genes was pivotal in defining a specific sar-
coma subtype7–9. Validated immunohistochemical analysis
of KIT and DOG1 facilitates the diagnosis of GIST10,11.
The more widely available mutation testing of KIT and
PDGFRA genes has led to a better understanding of the
clinical application of registered tyrosine kinase inhibitors
(TKIs) imatinib, sunitinib and regorafenib.
Wild-type GISTs are nowadays divided into succinate
dehydrogenase (SDH)-competent and SDH-deficient
tumours, with different oncogenic driver mutations in the
SDH-competent group9,12–14. It has become increasingly
important to genotype GISTs, as not all genotypes respond
equally to TKIs. These advances in the diagnosis and treat-
ment of GIST have changed rapidly and dramatically over
the past decade13,15–17.
The present study analysed the incidence and treatment
of GIST in an era with gradual advances in diagnosis,
imaging and systemic therapy. In addition, the long-term
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Table 1 Patient demographics and disease stage at diagnosis
2001–2004 (n=446) 2005–2008 (n=610) 2009–2012 (n=693) Total (n=1749)
Age at diagnosis (years)
Median 66 67 66 66
0–44 36 (8⋅1) 51 (8⋅4) 50 (7⋅2) 137 (7⋅8)
45–60 135 (30⋅3) 168 (27⋅5) 182 (26⋅3) 485 (27⋅7)
61–74 153 (34⋅3) 209 (34⋅3) 262 (37⋅8) 624 (35⋅7)
≥ 75 122 (27⋅4) 182 (29⋅8) 199 (28⋅7) 503 (28⋅8)
Sex ratio (M : F) 229 : 217 348 : 262 368 : 325 945 : 804
Tumour stage
Localized GIST 283 (63⋅5) 464 (76⋅1) 539 (77⋅8) 1286 (73⋅5)
Metastatic GIST 90 (20⋅2) 109 (17⋅9) 124 (17⋅9) 323 (18⋅5)
Unknown 73 (16⋅4) 37 (6⋅1) 30 (4⋅3) 140 (8⋅0)
(y)pT stage*
T0 (no tumour after preoperative treatment) 3 (0⋅7) 3 (0⋅7)
T1 (< 2 cm) 16 (3⋅9) 16 (3⋅9)
T2 (2–5 cm) 110 (27⋅0) 110 (27⋅0)
T3 (5–10 cm) 186 (45⋅7) 186 (45⋅7)
T4 (> 10 cm) 79 (19⋅4) 79 (19⋅4)
Tx (unknown) 13 (3⋅2) 13 (3⋅2)
Values in parentheses are percentages. *Data available only for 407 patients resected in 2010–2012. GIST, gastrointestinal stromal tumour.
outcomes of patients with GIST were analysed in compar-
ison with a nationwide population-based database.
Methods
Data were retrieved from the nationwide population-based
Netherlands Cancer Registry (NCR). Data from the NCR
are used both in clinical practice and for research pur-
poses. The NCR regularly receives overviews of patients
with newly diagnosed cancer from a nationwide pathol-
ogy network, in which pathology departments of all Dutch
hospitals participate. In addition, the medical records ser-
vices of hospitals provide overviews of diagnoses of cancer
in patients treated within outpatient and hospital settings.
Trained data managers extract data on patient and tumour
characteristics, and on primary treatment from the medi-
cal and pathology records. Data on survival were retrieved
by linkage to the nationwide population registries network.
Survival time was defined as time from diagnosis to death,
or until 1 January 2017 for patients who were still alive.
Different from a recent pathology study from the
Netherlands, all patients with a malignant GIST (as
defined in ICD-O-3, morphology code 8936/3) in
2001–2012 were included for analysis in the study and
micro-GIST were excluded18. As the NCR has been using
the ICD-O-3 morphology code for GISTs from 2001
onwards, this was chosen as a starting point. In previous
versions of the ICD-O, which were used by the NCR until
2000, no specific morphology code for GIST was available.
As there was no specific TNM classification for GISTs
until TNM-7, stage of disease at diagnosis was categorized
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Fig. 1 Incidence of gastrointestinal stromal tumour (GIST) in the
Netherlands, according to stage at diagnosis
and/or distant metastases). The pathological stage was used
if available; otherwise, the clinical stage was used to cate-
gorize patients. Data on mitotic rate are not registered in
the NCR. Data on completeness of surgery (R status) and
tumour size (T category) were available only from 2010.
Data in the NCR encompass primary treatment, defined as
the treatment a patient receives within the first 6–9months
after primary diagnosis, and categorized as surgery with
or without systemic treatment. No data on diagnosis and
treatment of recurrent disease are available in the NCR.
The incidence of GIST was calculated by dividing the
annual number of patients with GIST by the number of
inhabitants in the Netherlands in that particular year, and
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Table 2 Treatment of patients with a localized gastrointestinal stromal tumour in the first 6–9months after diagnosis
2001–2004 (n=283) 2005–2008 (n=464) 2009–2012 (n=539) Total (n=1286)
Surgery, no systemic therapy 229 (80⋅9) 335 (72⋅2) 358 (66⋅4) 922 (71⋅7)
Surgery and preoperative systemic therapy 10 (3⋅5) 36 (7⋅8) 40 (7⋅4) 86 (6⋅7)
Surgery and postoperative systemic therapy 6 (2⋅1) 39 (8⋅4) 49 (9⋅1) 94 (7⋅3)
Surgery and preoperative and postoperative systemic therapy 0 (0) 4 (0⋅9) 14 (2⋅6) 18 (1⋅4)
Systemic therapy, no surgery 21 (7⋅4) 36 (7⋅8) 48 (8⋅9) 105 (8⋅2)
Other or no treatment 17 (6⋅0) 14 (3⋅0) 30 (5⋅6) 61 (4⋅7)
Values in parentheses are percentages.
Table 3 Treatment of patients with metastatic gastrointestinal stromal tumour in the first 6–9months after diagnosis
2001–2004 (n=90) 2005–2008 (n=109) 2009–2012 (n=124) Total (n= 323)
Surgery, no systemic therapy 21 (23) 10 (9⋅2) 14 (11⋅3) 45 (13⋅9)
Surgery and preoperative systemic therapy 4 (4) 8 (7⋅3) 5 (4⋅0) 17 (5⋅3)
Surgery and postoperative systemic therapy 6 (7) 16 (14⋅7) 16 (12⋅9) 38 (11⋅8)
Surgery and preoperative and postoperative systemic therapy 1 (1) 1 (0⋅9) 7 (5⋅6) 9 (2⋅8)
Systemic therapy, no surgery 29 (32) 61 (56⋅0) 71 (57⋅3) 161 (49⋅8)
Other or no treatment 29 (32) 13 (11⋅9) 11 (8⋅9) 53 (16⋅4)
Values in parentheses are percentages.
age-standardized according to the European standard pop-
ulation. Changes in incidence were evaluated by calculating
the estimated annual percentage change (EAPC) with its
corresponding 95 per cent c.i.19.
The Cochran–Armitage trend test was used to assess for
differences over time. Three time frames of 4 years each
were used for analyses, thereby accounting for improve-
ments in diagnosis and application of TKIs.
Relative survival (RS), an internationally accepted
method that approaches disease-specific survival, was used
for survival calculations. As survival of certain subgroups
of patients with GIST can be very good, the RS rate can
exceed 100 per cent if it is greater than the survival of
the general population. RS is calculated by dividing the
absolute survival in the patient population by the expected
survival based on overall mortality of the Dutch population
matched for age and sex20. The estimation of RS becomes
unreliable when the group size is less than ten patients, in
which case the results are not presented.
Results
Incidence
A total of 1749 patients, 945 male and 804 female patients,
were diagnosed with GIST between January 2001 and
December 2012. At diagnosis, 1286 patients (73⋅5 per
cent) were diagnosed with non-metastatic GIST, 323 (18⋅5
per cent) with metastatic GIST, and for 140 patients (8⋅0
per cent) the disease stage was unknown. The specific
distributions of patient sex, age and disease stage are shown
in Table 1.
The incidence of non-metastatic GIST increased from
3⋅1 per million person-years in 2001 to 7⋅0 per million
person-years in 2012 (Fig. 1), and the EAPC was 7⋅1
(95 per cent c.i. 4⋅1 to 10⋅2) per cent (P< 0⋅001). After
2006, the incidence remained relatively stable. The inci-
dence for unknown disease stage decreased from 1⋅0 to
0⋅3 per million person-years between 2001 and 2012, with
an EAPC of −12⋅1 (−20⋅0 to −4⋅3) per cent (P= 0⋅004).
For primary metastatic GIST, the incidence was 1⋅3 per
million person-years in both 2001 and 2012 (P= 0⋅175).
The EAPC for all patients was 4⋅2 (2⋅3 to 6⋅2) per
cent (P= 0⋅001). The majority of GISTs were located
in the stomach (1020 patients, 58⋅3 per cent), followed
by the small intestine and duodenum (411 patients, 23⋅5
per cent), and rectum (69 patients, 3⋅9 per cent). In
249 patients (14⋅2 per cent) the location was unknown
or overlapping.
Treatment
The various treatment options undertaken in the 1286
patients (73⋅5 per cent) with non-metastatic GIST are
reported in Table 2. Only a small number of patients were
treated for very small (pT1) GIST lesions (3⋅9 per cent).
The majority of patients (922, 71⋅7 per cent) were oper-
ated on without receiving any systemic therapy. In the
first period (2001–2004), 16 patients (5⋅7 per cent) were
treated with some form of preoperative and/or postoper-
ative systemic treatment. This increased to 79 (17⋅0 per
cent) and 103 (19⋅1 per cent) respectively in the subse-
quent time periods of 2005–2008 and 2009–2012.Of all 57
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Table 4 Relative survival of patients with gastrointestinal stromal tumour according to Netherlands Cancer Registry standards
Survival (%)
No. of patients 1 year 3 years 5 years
Time interval
2001–2004 446 85⋅4 (81⋅5, 88⋅7) 77⋅8 (73⋅0, 82⋅1) 71⋅0 (65⋅6, 76⋅0)
2005–2008 610 90⋅3 (87⋅4, 92⋅8) 84⋅0 (80⋅1, 87⋅4) 79⋅0 (74⋅5, 83⋅1)
2009–2012 693 93⋅2 (90⋅7, 95⋅2) 85⋅1 (81⋅5, 88⋅2) 81⋅4 (77⋅3, 85⋅1)
Sex
M 945 89⋅5 (87⋅1, 91⋅6) 80⋅7 (77⋅5, 83⋅7) 74⋅9 (71⋅2, 78⋅4)
F 804 91⋅1 (88⋅7, 93⋅1) 85⋅4 (82⋅5, 88⋅2) 81⋅3 (77⋅6, 84⋅7)
Location
Stomach 1020 93⋅1 (91⋅1, 94⋅8) 87⋅7 (84⋅9, 90⋅2) 84⋅5 (81⋅2, 87⋅6)
Small intestine + duodenum 411 90⋅9 (87⋅4, 93⋅7) 83⋅8 (79⋅2, 87⋅8) 78⋅2 (72⋅8, 83⋅6)
Rectum 69 91⋅8 (81⋅1, 97⋅6) 84⋅1 (71⋅2, 93⋅2) 76⋅1 (61⋅8, 87⋅2)
Other 80 71⋅0 (59⋅2, 80⋅2) 58⋅6 (46⋅0, 69⋅6) 50⋅4 (37⋅7, 62⋅5)
Overlapping + GI location not otherwise specified 169 79⋅4 (72⋅0, 85⋅2) 62⋅3 (53⋅8, 70⋅0) 50⋅6 (41⋅8, 59⋅1)
Disease stage
Non-metastatic 1286 95⋅4 (93⋅8, 96⋅7) 90⋅8 (88⋅5, 92⋅9) 88⋅8 (86⋅0, 91⋅4)
Metastatic 323 81⋅1 (76⋅1, 85⋅3) 60⋅8 (54⋅8, 66⋅4) 48⋅2 (42⋅0, 54⋅2)
Unknown 140 63⋅2 (54⋅3, 71⋅1) 60⋅6 (51⋅1, 69⋅2) 46⋅7 (37⋅2, 56⋅0)
(y)pT stage*
T0 (no tumour after preoperative treatment) 3 † † †
T1–2 (< 5 cm) 126 101⋅0 (96⋅2, 101⋅7) 101⋅2 (95⋅2, 104⋅0) 102⋅4 (95⋅0, 106⋅6)
T3 (5–10 cm) 186 97⋅1 (92⋅6, 99⋅7) 95⋅8 (89⋅7,100⋅0) 94⋅4 (86⋅9, 100⋅1)
T4 (> 10 cm) 79 102⋅2‡ 94⋅9 (84⋅9, 100⋅5) 86⋅5 (73⋅8, 95⋅5)
Tx (unknown) 13 † † †
Radicality*
R0 323 99⋅2 (96⋅5,100⋅6) 97⋅6 (93⋅5, 100⋅5) 97⋅2 (92⋅1, 101⋅2)
R1/R2 39 99⋅4 (84⋅8, 101⋅6) 95⋅8 (80⋅0, 102⋅5) 83⋅4 (64⋅2, 95⋅9)
Unknown 45 97⋅3 (84⋅9, 100⋅6) 92⋅0 (77⋅2, 99⋅6) 89⋅0 (72⋅2, 99⋅2)
Non-metastatic GIST
Surgery, no systemic therapy 922 97⋅6 (95⋅9, 98⋅8) 94⋅9 (92⋅4, 97⋅1) 94⋅5 (91⋅4, 97⋅2)
Surgery and systemic therapy 198 97⋅5 (93⋅5, 99⋅5) 92⋅5 (86⋅9, 96⋅5) 90⋅4 (83⋅9, 95⋅3)
Systemic therapy, no surgery 105 88⋅6 (80⋅0, 94⋅2) 71⋅6 (60⋅6, 80⋅7) 61⋅5 (49⋅8, 72⋅2)
Other or no therapy 61 66⋅7 (52⋅4, 78⋅3) 54⋅3 (38⋅8, 68⋅9) 40⋅2 (25⋅0, 56⋅7)
Metastatic GIST
Surgery, no systemic therapy 45 86⋅9 (72⋅2, 95⋅0) 76⋅0 (59⋅3, 87⋅7) 67⋅0 (49⋅3, 81⋅2)
Surgery and systemic therapy 64 96⋅6 (87⋅3, 99⋅8) 89⋅7 (78⋅0, 96⋅5) 77⋅4 (63⋅6, 87⋅5)
Systemic therapy, no surgery 161 86⋅0 (79⋅2, 91⋅0) 55⋅4 (46⋅9, 63⋅4) 39⋅7 (31⋅4, 48⋅1)
Other or no therapy 53 41⋅6 (27⋅9, 55⋅0) 27⋅7 (15⋅8, 41⋅4) 21⋅0 (10⋅3, 34⋅8)
Values in parentheses are 95 per cent confidence intervals. *Data available only for 407 patients resected in 2010–2012. †Owing to low numbers of
patients, relative survival could not be calculated accurately. ‡As no deaths occurred during the first year, confidence intervals could not be calculated. GI,
gastrointestinal; GIST, gastrointestinal stromal tumour.
patients treated with preoperative imatinib in 2010–2012
who underwent surgery within 6–9months after diagnosis,
three patients had a complete pathological response after
resection. From 2010 onwards, the NCR contained data
on completeness of resection; 323 (79⋅4 per cent) of the
407 resected patients had an R0 resection and 39 (9⋅6 per
cent) an R1–R2 resection.
The different treatment modalities for the 323 patients
(18⋅5 per cent) with a primary metastatic GIST are shown
in Table 3. The proportion of patients who received sys-
temic treatment with no surgery in the 6–9-month interval
after diagnosis increased from 32 per cent in 2001–2004
to 57⋅3 per cent in 2009–2012, and presumably included
patients treated with neoadjuvant imatinib who had not yet
undergone surgery.
Relative survival
Median follow-up was 69⋅9 (range 0–192⋅7) months for all
patients. The 5-year RS rate for all patients increased from
71⋅0 (95 per cent c.i. 65⋅6 to 76⋅0) per cent in 2001–2004
to 81⋅4 (77⋅3 to 85⋅1) per cent in 2009–2012 (Table 4).
Women had a better 5-year RS rate than men: 81⋅3 (77⋅6 to
84⋅7) versus 74⋅9 (71⋅2 to 78⋅4) per cent respectively. As the
survival of patients with small tumours (pT1–2) was better
than that of the general population, the RS rate exceeded
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100 per cent. Patients with a gastric GIST had a 5-year RS
rate of 84⋅5 per cent versus 78⋅2, 76⋅1 and approximately
50 per cent for GISTs of the small intestine/duodenum,
rectum and other GI locations respectively. Patients with a
non-metastatic GIST had a 5-year RS rate of 88⋅8 (86⋅0 to
91⋅4) per cent.Of patients with a localizedGIST, those who
received surgery only had a better RS than patients who
had systemic therapy alone or a combination of surgery and
systemic therapy. For patients with a primary metastatic
GIST, the 5-year RS rate was 48⋅2 (42⋅0 to 54⋅2) per cent.
Patients who received systemic therapy before and/or after
surgery for primary metastatic GIST had a better RS rate
than those who had surgery or systemic therapy alone: 77⋅4
versus 67⋅0 and 39⋅7 per cent respectively.
Discussion
Since the introduction of imatinib in 2001 and the
improved diagnosis of GIST as a distinct histopathological
entity, both diagnosis and treatment of patients with GIST
have changed dramatically. The present study showed
the current incidence of GIST to be approximately 8 per
million population annually in the Netherlands, compara-
ble to data from other Western countries1–3,21. There is
considerable variation in the incidence of GIST reported
from different countries, which can be explained by a
number of factors. The diagnostic criteria have improved
over time as GISTs were commonly misdiagnosed before
2001, and the immunohistochemical identification of KIT
and DOG1 expression has made the reliable diagnosis of
GIST possible7,10,11,22. Therefore, patients with a GIST or
GIST-like tumour diagnosed before 2001 were excluded
from the present study, but will have been included in
some international reports4,5. Not all countries have estab-
lished cancer registries that register all GISTs, with the
consequence that smaller, low-risk tumours may not have
been reported1,23,24. Another reason for the difference in
incidence might be the lack of registries that score GISTs
as separate entities.
Patients with non-metastatic GIST demonstrated an
increased incidence from 3⋅1 in 2001 to 7⋅0 in 2012
per million person-years, with a significant increase in
the EAPC of 7⋅1 per cent. However, the number of
patients with unknown stage presentation decreased dur-
ing the same period owing to better staging and reg-
istration; this might partly explain the increased EAPC
for localized GIST. From 2006 onwards, the incidence
remained stable.
Risk classification of GIST has developed over time,
including not only tumour size, but also location and
mitotic rate. More recently, tumour rupture and GIST
genotype have been added to risk classifications25–29. High
tumour mitotic count, non-gastric location, large tumour
size, rupture during surgery, and adjuvant imatinib for
12 rather than 36months, were independently associated
with a lower recurrence-free survival rate in patients with
GIST29,30.
A limitation of the present study is that theNCRdatabase
lacks information on mitotic rate and tumour rupture,
although data on tumour size, sex, location, stage and com-
pleteness of resection are available, and were recognized
as significant prognostic factors. Other studies6,31,32 have
also shown patient sex to be a prognostic factor in GIST.
The BRF14 trial of the French Sarcoma Group32, which
solely included patients with metastatic disease who were
started on imatinib, showed a highly significant 5-year sur-
vival benefit for women of 76⋅5 per cent, versus 53⋅5 per
cent in men. A clear explanation for this sex difference has
not yet been found, but the present data showed a similar
favourable outcome for women.
Surgery is the most important treatment modality lead-
ing to cure in low-risk tumours. In patients with low-grade
GISTs, 5-year survival rates as high as 95–100 per cent
have been reported in the literature29, and this was also
demonstrated in the present cohort. For high-risk patients,
the introduction of adjuvant imatinib has also led to
improved survival rates. The stomach is the most com-
monly affected GI site in patients with a localized GIST,
and is associated with the most favourable prognosis, with
a 5-year survival rate of 84⋅5 per cent reported in the
present study. This is comparable with survival data from
other studies33, including a large cohort from Korea and
Japan34. There may be a bias in these survival rates when
compared to other GI locations, because gastric GISTs
are generally discovered at an earlier disease stage. In the
present study, only 3⋅9 per cent of removed tumours were
smaller than 2 cm (pT1), and the majority of patients with
non-metastatic GIST were treated with surgery alone. An
increasing number of patients with larger tumours were
treated with preoperative and/or postoperative systemic
treatment. This is explained partly by adjuvant treatment
with imatinib for high-risk patients, as demonstrated by
Joensuu and colleagues30. Patients with locally advanced
GISTs have also increasingly been treated with preopera-
tive imatinib, leading to excellent downsizing and reduc-
tion of peroperative tumour rupture35,36. In the present
study, earlier cohorts of patients with high-risk GIST
treated before 2012 did not receive adjuvant imatinib,
which may have had an impact on the survival results of
high-risk patients in that period.
The annual incidence of patients presenting with
metastatic GIST remained fairly constant over time, with
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a non-significant change in the EAPC of 2⋅4 per cent. The
increased use of TKIs in patients with metastatic GIST
improved their overall survival significantly17,37. Before
TKIs were available, patients with metastatic GIST had
a median survival of 10–20 months38–40, but this has
subsequently increased to more than 4 years, with further
improvements in survival over time and differences depen-
dent on molecular subtypes32,41. The reported 5-year
survival rate of 48⋅2 per cent for patients with primary
metastasized GIST in the present study is in line with
the outcome data of these clinical studies17,37,41, which is
remarkable as the NCR encompasses population-based
data. All patients, including the elderly and patients with
very advanced disease or severe co-morbidity, are included
in the nationwide database, whereas such patients are
usually excluded from clinical trials.
In the present population, patients with metastatic GIST
who underwent surgery with or without systemic therapy
had much higher 5-year RS rates than patients treated with
systemic therapy alone (77⋅4 versus 67⋅0 and 39⋅7 per cent
respectively). This could be a result of patient selection
and bias, although other studies42,43 have demonstrated
an indication for surgery in metastatic GIST, as long as
the patient does not have progressive disease. In the NCR
database, treatment data are recorded for a maximum of
9months after diagnosis, which means information on
surgery beyond 9months is lacking, particularly after pre-
operative systemic treatment. Not only patients with local
recurrence or intra-abdominal metastatic lesions were
operated on, but also those with hepatic metastases treated
with both systemic treatment and surgery, leading to excel-
lent long-term survival in carefully selected patients44,45.
Treatment within the context of multidisciplinary teams
with expertise in GIST and in clinical studies remains
crucial for further improvement in the outcome of patients
with GIST46.
The present study demonstrates a stable incidence of
GIST in the Netherlands of approximately 8 per mil-
lion person-years, with one in five patients presenting
with metastatic disease. Women and patients with gastric
GIST have the best prognosis. In the imatinib era, RS has
improved significantly over time for all patients with GIST.
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Snapshot quiz 18/8
Answer: This 40-year-old labourer presented with a 2-day history of central chest pain radiating to his back following
the left lung base, and subcutaneous emphysema across the thorax consistent with Boerhaave syndrome (ruptured
oesophagus). He was tachycardic and hypoxic. CT demonstrated mediastinal emphysema and a large left pleural
was closed primarily. Lavage and large-bore drainage of the mediastinal cavity and thorax was performed.
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